{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:01:32Z","timestamp":1792242092664,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2019,11]]},"abstract":"Abstract<\/jats:title>\n \n Rationale<\/jats:title>\n Impulsive aggressive behavior is associated with reduced central function of serotonin (5\u2010HT). Although selective serotonin reuptake inhibitors can reduce such behaviors, many with history of impulsive aggression do not respond adequately to selective serotonin reuptake inhibitors and may require treatment with a direct 5\u2010HT agonist.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To test the hypothesis that pretreatment with the selective 5\u2010HT2c agonist, lorcaserin, can reduce aggressive responding in impulsively aggressive individuals.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Ten male and female adults were given lorcaserin (20 mg), or a matching placebo, in random order, on 2 days separated by at least 1 week. The Taylor aggression paradigm was used to assess aggressive responding, which was represented by mean shock setting administered to an opponent and by frequency of setting high and extreme shock levels to the opponent.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Compared with placebo, lorcaserin attenuated provoked, but not unprovoked, aggression during the Taylor aggression paradigm. This was manifest by reduction in the frequency of selecting high and extreme levels of shock against the opponent.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Lorcaserin may possess anti\u2010aggressive properties that could prove useful in the treatment of impulsive aggressive behavior in human subjects. These data, thus, provide a rationale for a follow\u2010up randomized clinical trial of lorcaserin in individuals with prominent histories of impulsive aggressive behavior.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/hup.2714","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T10:32:36Z","timestamp":1574850756000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["5\u2010HT\n 2c<\/sub>\n agonist, lorcaserin, reduces aggressive responding in intermittent explosive disorder: A pilot study"],"prefix":"10.1002","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1595-0266","authenticated-orcid":false,"given":"Emil F.","family":"Coccaro","sequence":"first","affiliation":[{"name":"Clinical Neuroscience Research Unit, Department of Psychiatry and Behavioral Neuroscience, Pritzker School of Medicine The University of Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Royce J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Neuroscience Research Unit, Department of Psychiatry and Behavioral Neuroscience, Pritzker School of Medicine The University of Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2010.02.012"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1037\/1089-2680.1.1.19"},{"key":"e_1_2_8_5_1","first-page":"1","article-title":"The use of lorcaserin in the management of obesity: A critical appraisal","volume":"5","author":"Bai B.","year":"2010","journal-title":"Drug Design, Development and Therapy"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9280.2009.02355.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-3514.63.3.452"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.11081259"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00119-4"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2016.07.010"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830240035005"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00309-0"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246407"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04150"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2009.07.004"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.148"},{"key":"e_1_2_8_17_1","first-page":"3","volume-title":"Aggression: Clinical features and treatment across the diagnostic spectrum","author":"Coccaro E. F.","year":"2019"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810070013002"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.8.1158"},{"key":"e_1_2_8_20_1","volume-title":"Structured clinical interview for DSM\u20105 patient edition (SCID\u2010P)","author":"First M. B.","year":"2014"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(94)00876-0"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05256gry"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830110037005"},{"key":"e_1_2_8_24_1","volume-title":"Structured interview for DSM\u2010IV personality: SIDP\u2010IV","author":"Pfohl B.","year":"1997"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199502000-00005"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/YPG.0b013e328335125d"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133348"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2714","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hup.2714","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:19:12Z","timestamp":1694218752000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/hup.2714"],"URL":"https:\/\/doi.org\/10.1002\/hup.2714","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"2019-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2714"}}